Immunogenicity and efficacy of mRNA COVID-19 vaccine MRT5500 in preclinical animal models
Abstract Emergency use authorization of COVID vaccines has brought hope to mitigate pandemic of coronavirus disease 2019 (COVID-19). However, there remains a need for additional effective vaccines to meet the global demand and address the potential new viral variants. mRNA technologies offer an expe...
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2021-04-01
|
Series: | npj Vaccines |
Online Access: | https://doi.org/10.1038/s41541-021-00324-5 |
_version_ | 1797643075178201088 |
---|---|
author | Kirill V. Kalnin Timothy Plitnik Michael Kishko Jinrong Zhang Donghui Zhang Adrien Beauvais Natalie G. Anosova Tim Tibbitts Josh DiNapoli Gregory Ulinski Peter Piepenhagen Sheila M. Cummings Dinesh S. Bangari Susan Ryan Po-Wei D. Huang James Huleatt Deanne Vincent Katherine Fries Shrirang Karve Rebecca Goldman Hardip Gopani Anusha Dias Khang Tran Minnie Zacharia Xiaobo Gu Lianne Boeglin Jonathan Abysalh Jorel Vargas Angela Beaulieu Monic Shah Travis Jeannotte Kimberly Gillis Sudha Chivukula Ron Swearingen Victoria Landolfi Tong-Ming Fu Frank DeRosa Danilo Casimiro |
author_facet | Kirill V. Kalnin Timothy Plitnik Michael Kishko Jinrong Zhang Donghui Zhang Adrien Beauvais Natalie G. Anosova Tim Tibbitts Josh DiNapoli Gregory Ulinski Peter Piepenhagen Sheila M. Cummings Dinesh S. Bangari Susan Ryan Po-Wei D. Huang James Huleatt Deanne Vincent Katherine Fries Shrirang Karve Rebecca Goldman Hardip Gopani Anusha Dias Khang Tran Minnie Zacharia Xiaobo Gu Lianne Boeglin Jonathan Abysalh Jorel Vargas Angela Beaulieu Monic Shah Travis Jeannotte Kimberly Gillis Sudha Chivukula Ron Swearingen Victoria Landolfi Tong-Ming Fu Frank DeRosa Danilo Casimiro |
author_sort | Kirill V. Kalnin |
collection | DOAJ |
description | Abstract Emergency use authorization of COVID vaccines has brought hope to mitigate pandemic of coronavirus disease 2019 (COVID-19). However, there remains a need for additional effective vaccines to meet the global demand and address the potential new viral variants. mRNA technologies offer an expeditious path alternative to traditional vaccine approaches. Here we describe the efforts to utilize an mRNA platform for rational design and evaluations of mRNA vaccine candidates based on the spike (S) glycoprotein of SARS-CoV-2. Several mRNA constructs of S-protein, including wild type, a pre-fusion stabilized mutant (2P), a furin cleavage-site mutant (GSAS) and a double mutant form (2P/GSAS), as well as others, were tested in animal models for their capacity to elicit neutralizing antibodies (nAbs). The lead 2P/GSAS candidate was further assessed in dose-ranging studies in mice and Cynomolgus macaques, and for efficacy in a Syrian golden hamster model. The selected 2P/GSAS vaccine formulation, designated MRT5500, elicited potent nAbs as measured in neutralization assays in all three preclinical models and more importantly, protected against SARS-CoV-2-induced weight loss and lung pathology in hamsters. In addition, MRT5500 elicited TH1-biased responses in both mouse and non-human primate (NHP), thus alleviating a hypothetical concern of potential vaccine-associated enhanced respiratory diseases known associated with TH2-biased responses. These data position MRT5500 as a viable vaccine candidate for entering clinical development. |
first_indexed | 2024-03-11T14:09:25Z |
format | Article |
id | doaj.art-9fae835e0be047258ae7c50814033e8c |
institution | Directory Open Access Journal |
issn | 2059-0105 |
language | English |
last_indexed | 2024-03-11T14:09:25Z |
publishDate | 2021-04-01 |
publisher | Nature Portfolio |
record_format | Article |
series | npj Vaccines |
spelling | doaj.art-9fae835e0be047258ae7c50814033e8c2023-11-02T00:40:41ZengNature Portfolionpj Vaccines2059-01052021-04-016111210.1038/s41541-021-00324-5Immunogenicity and efficacy of mRNA COVID-19 vaccine MRT5500 in preclinical animal modelsKirill V. Kalnin0Timothy Plitnik1Michael Kishko2Jinrong Zhang3Donghui Zhang4Adrien Beauvais5Natalie G. Anosova6Tim Tibbitts7Josh DiNapoli8Gregory Ulinski9Peter Piepenhagen10Sheila M. Cummings11Dinesh S. Bangari12Susan Ryan13Po-Wei D. Huang14James Huleatt15Deanne Vincent16Katherine Fries17Shrirang Karve18Rebecca Goldman19Hardip Gopani20Anusha Dias21Khang Tran22Minnie Zacharia23Xiaobo Gu24Lianne Boeglin25Jonathan Abysalh26Jorel Vargas27Angela Beaulieu28Monic Shah29Travis Jeannotte30Kimberly Gillis31Sudha Chivukula32Ron Swearingen33Victoria Landolfi34Tong-Ming Fu35Frank DeRosa36Danilo Casimiro37Sanofi PasteurYoh Services LLCSanofi PasteurSanofi PasteurSanofi PasteurSanofi PasteurSanofi PasteurSanofi PasteurSanofi PasteurGlobal Discovery Pathology, SanofiGlobal Discovery Pathology, SanofiGlobal Discovery Pathology, SanofiGlobal Discovery Pathology, SanofiGlobal Discovery Pathology, SanofiSanofi PasteurSanofi PasteurSanofi PasteurSanofi PasteurTranslate BioTranslate BioTranslate BioTranslate BioTranslate BioTranslate BioTranslate BioTranslate BioTranslate BioTranslate BioTranslate BioTranslate BioTranslate BioTranslate BioSanofi PasteurTranslate BioSanofi PasteurSanofi PasteurTranslate BioSanofi PasteurAbstract Emergency use authorization of COVID vaccines has brought hope to mitigate pandemic of coronavirus disease 2019 (COVID-19). However, there remains a need for additional effective vaccines to meet the global demand and address the potential new viral variants. mRNA technologies offer an expeditious path alternative to traditional vaccine approaches. Here we describe the efforts to utilize an mRNA platform for rational design and evaluations of mRNA vaccine candidates based on the spike (S) glycoprotein of SARS-CoV-2. Several mRNA constructs of S-protein, including wild type, a pre-fusion stabilized mutant (2P), a furin cleavage-site mutant (GSAS) and a double mutant form (2P/GSAS), as well as others, were tested in animal models for their capacity to elicit neutralizing antibodies (nAbs). The lead 2P/GSAS candidate was further assessed in dose-ranging studies in mice and Cynomolgus macaques, and for efficacy in a Syrian golden hamster model. The selected 2P/GSAS vaccine formulation, designated MRT5500, elicited potent nAbs as measured in neutralization assays in all three preclinical models and more importantly, protected against SARS-CoV-2-induced weight loss and lung pathology in hamsters. In addition, MRT5500 elicited TH1-biased responses in both mouse and non-human primate (NHP), thus alleviating a hypothetical concern of potential vaccine-associated enhanced respiratory diseases known associated with TH2-biased responses. These data position MRT5500 as a viable vaccine candidate for entering clinical development.https://doi.org/10.1038/s41541-021-00324-5 |
spellingShingle | Kirill V. Kalnin Timothy Plitnik Michael Kishko Jinrong Zhang Donghui Zhang Adrien Beauvais Natalie G. Anosova Tim Tibbitts Josh DiNapoli Gregory Ulinski Peter Piepenhagen Sheila M. Cummings Dinesh S. Bangari Susan Ryan Po-Wei D. Huang James Huleatt Deanne Vincent Katherine Fries Shrirang Karve Rebecca Goldman Hardip Gopani Anusha Dias Khang Tran Minnie Zacharia Xiaobo Gu Lianne Boeglin Jonathan Abysalh Jorel Vargas Angela Beaulieu Monic Shah Travis Jeannotte Kimberly Gillis Sudha Chivukula Ron Swearingen Victoria Landolfi Tong-Ming Fu Frank DeRosa Danilo Casimiro Immunogenicity and efficacy of mRNA COVID-19 vaccine MRT5500 in preclinical animal models npj Vaccines |
title | Immunogenicity and efficacy of mRNA COVID-19 vaccine MRT5500 in preclinical animal models |
title_full | Immunogenicity and efficacy of mRNA COVID-19 vaccine MRT5500 in preclinical animal models |
title_fullStr | Immunogenicity and efficacy of mRNA COVID-19 vaccine MRT5500 in preclinical animal models |
title_full_unstemmed | Immunogenicity and efficacy of mRNA COVID-19 vaccine MRT5500 in preclinical animal models |
title_short | Immunogenicity and efficacy of mRNA COVID-19 vaccine MRT5500 in preclinical animal models |
title_sort | immunogenicity and efficacy of mrna covid 19 vaccine mrt5500 in preclinical animal models |
url | https://doi.org/10.1038/s41541-021-00324-5 |
work_keys_str_mv | AT kirillvkalnin immunogenicityandefficacyofmrnacovid19vaccinemrt5500inpreclinicalanimalmodels AT timothyplitnik immunogenicityandefficacyofmrnacovid19vaccinemrt5500inpreclinicalanimalmodels AT michaelkishko immunogenicityandefficacyofmrnacovid19vaccinemrt5500inpreclinicalanimalmodels AT jinrongzhang immunogenicityandefficacyofmrnacovid19vaccinemrt5500inpreclinicalanimalmodels AT donghuizhang immunogenicityandefficacyofmrnacovid19vaccinemrt5500inpreclinicalanimalmodels AT adrienbeauvais immunogenicityandefficacyofmrnacovid19vaccinemrt5500inpreclinicalanimalmodels AT natalieganosova immunogenicityandefficacyofmrnacovid19vaccinemrt5500inpreclinicalanimalmodels AT timtibbitts immunogenicityandefficacyofmrnacovid19vaccinemrt5500inpreclinicalanimalmodels AT joshdinapoli immunogenicityandefficacyofmrnacovid19vaccinemrt5500inpreclinicalanimalmodels AT gregoryulinski immunogenicityandefficacyofmrnacovid19vaccinemrt5500inpreclinicalanimalmodels AT peterpiepenhagen immunogenicityandefficacyofmrnacovid19vaccinemrt5500inpreclinicalanimalmodels AT sheilamcummings immunogenicityandefficacyofmrnacovid19vaccinemrt5500inpreclinicalanimalmodels AT dineshsbangari immunogenicityandefficacyofmrnacovid19vaccinemrt5500inpreclinicalanimalmodels AT susanryan immunogenicityandefficacyofmrnacovid19vaccinemrt5500inpreclinicalanimalmodels AT poweidhuang immunogenicityandefficacyofmrnacovid19vaccinemrt5500inpreclinicalanimalmodels AT jameshuleatt immunogenicityandefficacyofmrnacovid19vaccinemrt5500inpreclinicalanimalmodels AT deannevincent immunogenicityandefficacyofmrnacovid19vaccinemrt5500inpreclinicalanimalmodels AT katherinefries immunogenicityandefficacyofmrnacovid19vaccinemrt5500inpreclinicalanimalmodels AT shrirangkarve immunogenicityandefficacyofmrnacovid19vaccinemrt5500inpreclinicalanimalmodels AT rebeccagoldman immunogenicityandefficacyofmrnacovid19vaccinemrt5500inpreclinicalanimalmodels AT hardipgopani immunogenicityandefficacyofmrnacovid19vaccinemrt5500inpreclinicalanimalmodels AT anushadias immunogenicityandefficacyofmrnacovid19vaccinemrt5500inpreclinicalanimalmodels AT khangtran immunogenicityandefficacyofmrnacovid19vaccinemrt5500inpreclinicalanimalmodels AT minniezacharia immunogenicityandefficacyofmrnacovid19vaccinemrt5500inpreclinicalanimalmodels AT xiaobogu immunogenicityandefficacyofmrnacovid19vaccinemrt5500inpreclinicalanimalmodels AT lianneboeglin immunogenicityandefficacyofmrnacovid19vaccinemrt5500inpreclinicalanimalmodels AT jonathanabysalh immunogenicityandefficacyofmrnacovid19vaccinemrt5500inpreclinicalanimalmodels AT jorelvargas immunogenicityandefficacyofmrnacovid19vaccinemrt5500inpreclinicalanimalmodels AT angelabeaulieu immunogenicityandefficacyofmrnacovid19vaccinemrt5500inpreclinicalanimalmodels AT monicshah immunogenicityandefficacyofmrnacovid19vaccinemrt5500inpreclinicalanimalmodels AT travisjeannotte immunogenicityandefficacyofmrnacovid19vaccinemrt5500inpreclinicalanimalmodels AT kimberlygillis immunogenicityandefficacyofmrnacovid19vaccinemrt5500inpreclinicalanimalmodels AT sudhachivukula immunogenicityandefficacyofmrnacovid19vaccinemrt5500inpreclinicalanimalmodels AT ronswearingen immunogenicityandefficacyofmrnacovid19vaccinemrt5500inpreclinicalanimalmodels AT victorialandolfi immunogenicityandefficacyofmrnacovid19vaccinemrt5500inpreclinicalanimalmodels AT tongmingfu immunogenicityandefficacyofmrnacovid19vaccinemrt5500inpreclinicalanimalmodels AT frankderosa immunogenicityandefficacyofmrnacovid19vaccinemrt5500inpreclinicalanimalmodels AT danilocasimiro immunogenicityandefficacyofmrnacovid19vaccinemrt5500inpreclinicalanimalmodels |